A Phase II Evaluation of Sunitinib Malate (Sutent, SU11248, NCI-Supplied Agent , NSC 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

Trial Profile

A Phase II Evaluation of Sunitinib Malate (Sutent, SU11248, NCI-Supplied Agent , NSC 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Leiomyosarcoma; Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2010 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov record.
    • 09 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Oct 2008 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top